The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJp Morg.as Regulatory News (JAGI)

Share Price Information for Jp Morg.as (JAGI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 370.00
Bid: 368.00
Ask: 370.00
Change: 2.00 (0.54%)
Spread: 2.00 (0.543%)
Open: 370.00
High: 370.00
Low: 368.00
Prev. Close: 368.00
JAGI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results analysis from Kepler Trust Intelligence

19 Dec 2023 14:27

RNS Number : 3490X
JPMorgan Asia Growth & Income PLC
19 December 2023
 

JPMorgan Asia Growth & Income (JAGI)

19/12/2023

Results analysis from Kepler Trust Intelligence

JPMorgan Asia Growth & Income (JAGI) has released its results for the year ending 30/09/2023. The trust delivered strong absolute and relative returns, with NAV and share price total returns of 6.4% and 7.3% respectively. The trust's benchmark, the MSCI Asia ex-Japan Index, delivered equivalent returns of 1.4% over the period.

Long-term performance remains strong. JAGI has outperformed every year bar one over the last decade. Annualised NAV total returns in that period were 8.5%, compared to 6.5% for the benchmark.

The trust continued its policy of paying four quarterly dividends, equal to 1% of NAV at quarter end. Dividends for the year totalled 15.7p, representing a small decline on the prior year, when dividends totalled 16.5p.

JAGI's discount tightened during the year, from 9.6% to 9.2% at the period end. This has since widened to 10% as at 13/12/2023. The trust engages in buybacks to manage the discount. In the year, the trust repurchased 5.7m shares, equal to 5.9% of share capital at the start of the period.

JAGI Chairman Sir Richard Stagg said: "The Company has the chance to invest in innovative, often world-leading businesses. With valuations across most of the region at long-term lows relative to both historic levels and to the US and Europe, now seems a particularly auspicious moment to be investing in Asia. We are therefore confident of the Company's capacity to continue delivering capital gains and an attractive income to shareholders over the long term."

JPMorgan Asia Growth & Income (JAGI) aims to provide investors with core exposure to Asia by investing in a portfolio of quality companies. The trust makes full use of its closed-ended structure to pay a dividend equal to 1% of NAV at the end of each quarter, paying from both revenue and capital reserves. We believe this approach allows the managers to focus on the best opportunities to drive total returns, rather than having to factor in yield considerations.

The trust has delivered consistent outperformance over the past decade, with only one year in which the managers failed to outperform. Last year was no different and, after a tough 2022 for Asia investors, the managers managed to deliver strong performance despite negative sentiment around China.

We think the managers' stock picking process also proved itself in 2023. Partly that was reflected in underweight positions to Chinese e-commerce. This is a sector which has become increasingly competitive and subject to more regulatory pressure, crimping returns for investors in the sector. At the same time, JAGI's overweight position to technology companies supported outperformance. We would note that this was not confined to 'mega' caps like TSMC or Samsung, as Taiwanese hardware company Wiwynn and Korean semiconductor manufacturer SK Hynix also drove outperformance for the trust.

We think those positions reflect the huge opportunity that Asia represents today. The continent looks set to be the engine of global growth in the next quarter century. Research from the Brookings Institute, a US think tank, indicates that the proportion of the global consumer class in Asia will rise to 80% by the end of this decade, up from approximately 50% today and barely 20% at the start of the century.

Demography is not destiny but the JAGI managers have proven themselves capable of sorting the wheat from the chaff in the region. As we noted in our latest research on the trust, JAGI is now trading at a discount that is substantially wider than its five year average. With rate hikes potentially having peaked and Asian companies also trading at low valuations, relative to both other regions and their own historical average, it's plausible we'll see a tightening of that discount if performance continues to be strong into 2024.

CLICK HERE TO READ THE FULL REPORT  Visit Kepler Trust Intelligence for more high quality independent investment trust research.

 

Important information

This report has been issued by Kepler Partners LLP. The analyst who has prepared this report is aware that Kepler Partners LLP has a relationship with the company covered in this report and/or a conflict of interest which may impair the objectivity of the research.

Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise and you may get back less than you invested when you decide to sell your investments. It is strongly recommended that if you are a private investor independent financial advice should be taken before making any investment or financial decision.

Kepler Partners is not authorised to make recommendations to retail clients. This report has been issued by Kepler Partners LLP, is based on factual information only, is solely for information purposes only and any views contained in it must not be construed as investment or tax advice or a recommendation to buy, sell or take any action in relation to any investment.

The information provided on this website is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Kepler Partners LLP to any registration requirement within such jurisdiction or country. In particular, this website is exclusively for non-US Persons. Persons who access this information are required to inform themselves and to comply with any such restrictions.

The information contained in this website is not intended to constitute, and should not be construed as, investment advice. No representation or warranty, express or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. Any views and opinions, whilst given in good faith, are subject to change without notice.

This is not an official confirmation of terms and is not a recommendation, offer or solicitation to buy or sell or take any action in relation to any investment mentioned herein. Any prices or quotations contained herein are indicative only.

Kepler Partners LLP (including its partners, employees and representatives) or a connected person may have positions in or options on the securities detailed in this report, and may buy, sell or offer to purchase or sell such securities from time to time, but will at all times be subject to restrictions imposed by the firm's internal rules. A copy of the firm's Conflict of Interest policy is available on request.

PLEASE SEE ALSO OUR TERMS AND CONDITIONS

Kepler Partners LLP is authorised and regulated by the Financial Conduct Authority (FRN 480590), registered in England and Wales at 70 Conduit Street, London W1S 2GF with registered number OC334771.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFLFFSFELALIV
Date   Source Headline
23rd May 20245:01 pmRNSTransaction in Own Shares
23rd May 202410:36 amRNSNet Asset Value(s)
22nd May 20245:09 pmRNSTransaction in Own Shares
22nd May 202411:08 amRNSNet Asset Value(s)
21st May 202411:39 amRNSNet Asset Value(s)
20th May 20245:17 pmRNSTransaction in Own Shares
20th May 202411:56 amRNSGearing Announcement
20th May 202410:45 amRNSNet Asset Value(s)
17th May 202410:40 amRNSNet Asset Value(s)
16th May 20245:11 pmRNSTransaction in Own Shares
16th May 202410:37 amRNSNet Asset Value(s)
15th May 20244:59 pmRNSTransaction in Own Shares
15th May 202410:25 amRNSNet Asset Value(s)
14th May 20244:51 pmRNSTransaction in Own Shares
14th May 202410:52 amRNSNet Asset Value(s)
13th May 20245:01 pmRNSTransaction in Own Shares
13th May 202411:22 amRNSGearing announcement
13th May 202410:56 amRNSNet Asset Value(s)
13th May 20249:52 amRNSTen Largest Investments
10th May 20245:14 pmRNSTransaction in Own Shares
10th May 202410:59 amRNSNet Asset Value(s)
9th May 20244:57 pmRNSTransaction in Own Shares
9th May 202410:34 amRNSNet Asset Value(s)
8th May 20245:08 pmRNSTransaction in Own Shares
8th May 202410:24 amRNSNet Asset Value(s)
7th May 202411:47 amRNSGearing announcement
7th May 202411:09 amRNSNet Asset Value(s)
3rd May 202410:57 amRNSNet Asset Value(s)
2nd May 202411:19 amRNSNet Asset Value(s)
1st May 202411:23 amRNSNet Asset Value(s)
1st May 202410:26 amRNSTotal Voting Rights
30th Apr 20245:10 pmRNSTransaction in Own Shares
30th Apr 202411:06 amRNSNet Asset Value(s)
29th Apr 202412:03 pmRNSGearing Announcement
29th Apr 202411:05 amRNSNet Asset Value(s)
26th Apr 202410:48 amRNSNet Asset Value(s)
25th Apr 20245:00 pmRNSTransaction in Own Shares
25th Apr 202410:11 amRNSNet Asset Value(s)
24th Apr 20245:24 pmRNSTransaction in Own Shares
24th Apr 202410:19 amRNSNet Asset Value(s)
23rd Apr 20245:01 pmRNSTransaction in Own Shares
23rd Apr 202410:31 amRNSNet Asset Value(s)
22nd Apr 20245:02 pmRNSTransaction in Own Shares
22nd Apr 202411:20 amRNSGearing announcement
22nd Apr 202410:48 amRNSNet Asset Value(s)
19th Apr 202410:26 amRNSNet Asset Value(s)
18th Apr 20245:04 pmRNSTransaction in Own Shares
18th Apr 202410:52 amRNSNet Asset Value(s)
17th Apr 202410:43 amRNSNet Asset Value(s)
16th Apr 20245:04 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.